| 头颈部鳞癌免疫检查点抑制剂治疗专家共识 |
| |
| 引用本文： | 刘磊,向中正,李一,郭伟,杨凯,王军,孙志军,任国欣,张建国,孙沫逸,冉伟,黄桂林,唐瞻贵,李龙江. 头颈部鳞癌免疫检查点抑制剂治疗专家共识[J]. 华西口腔医学杂志, 2022, 40(6): 619-628. DOI: 10.7518/hxkq.2022.06.001 |
| |
| 作者姓名： | 刘磊 向中正 李一 郭伟 杨凯 王军 孙志军 任国欣 张建国 孙沫逸 冉伟 黄桂林 唐瞻贵 李龙江 |
| |
| 作者单位： | 四川大学华西医院头颈肿瘤科,成都610041;口腔疾病研究国家重点实验室 国家口腔疾病临床医学研究中心四川大学华西口腔医院头颈肿瘤外科,成都610041;上海交通大学医学院附属第九人民医院口腔颌面头颈肿瘤外科,上海200011;重庆医科大学附属第一医院口腔颌面外科,重庆400016;武汉大学口腔医院口腔颌面外科,武汉430079;北京大学口腔医院口腔颌面外科,北京100081;空军医科大学口腔医院口腔颌面外科,西安710032;中山大学附属第一医院口腔颌面外科,广州510080;遵义医科大学口腔医院口腔颌面外科,遵义563000;中南大学湘雅口腔医院口腔颌面外科,长沙410000 |
| |
| 基金项目： | 国家自然科学基金肿瘤专项(82141130) |
| |
| 摘 要： | 近年来免疫检查点抑制剂（ICIs）在恶性肿瘤治疗中有着突破性进展，并迅速被批准作为多系统恶性肿瘤的一线治疗方案。在头颈部鳞癌中，帕博利珠单抗单药或联合化疗方案已被国内外指南推荐用于复发/转移头颈部鳞癌的一线治疗。虽然ICIs在头颈部鳞癌治疗中有里程碑的意义，但当前仍然存在诸多需要重视的问题，如ICIs疗效预测因子的选择，肿瘤病灶对ICIs治疗反应的评价，免疫超进展的应对以及免疫相关不良反应的处理等。因此，本共识基于当前临床已有的循证医学依据，结合临床上关注的热点问题进行深入探讨，整合头颈部肿瘤各专业领域专家的临床工作经验而形成相对规范统一的认识。
|
| 关 键 词： | 头颈部鳞癌 免疫治疗 免疫检查点抑制剂 专家共识 |
| 收稿时间： | 2022-04-11 |
| 修稿时间： | 2022-09-18 |
The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus |
| |
| Liu Lei,Xiang Zhongzheng,Li Yi,Guo Wei,Yang Kai,Wang Jun,Sun Zhijun,Ren Guoxin,Zhang Jianguo,Sun Moyi,Ran Wei,Huang Guilin,Tang Zhangui,Li Longjiang. The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus[J]. West China journal of stomatology, 2022, 40(6): 619-628. DOI: 10.7518/hxkq.2022.06.001 |
| |
| Authors: | Liu Lei Xiang Zhongzheng Li Yi Guo Wei Yang Kai Wang Jun Sun Zhijun Ren Guoxin Zhang Jianguo Sun Moyi Ran Wei Huang Guilin Tang Zhangui Li Longjiang |
| |
| Abstract: | Immune checkpoint inhibitors (ICIs) present significant efficacy in the treatment of malignant tumors, and they have been approved as the first-line of treatment for various cancers. Pembrolizumab monotherapy or combined with chemotherapy has been recommended by domestic and foreign guidelines for the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma. Although ICIs represent a milestone in the treatment of head and neck squamous cell carcinoma, potential problems still need to be addressed, such as the selection of the efficacy predictors for ICIs, the evaluation of the tumor response to ICIs, and the treatment of immune hyperprogression and immune-related adverse events. Therefore, to form a relatively unified understanding of ICIs treatment for head and neck squamous cell carcinoma, we integrated the clinical experience of multi-disciplinary experts of head and neck cancers on the basis of current clinical hot issues and finally developed this consensus. |
| |
| Keywords: | head and neck squamous cell carcinoma immunotherapy immune checkpoint inhibitors expert consensus |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《华西口腔医学杂志》浏览原始摘要信息 |
|
点击此处可从《华西口腔医学杂志》下载全文 |
|
